Menu Search
Equities

Zhongzhi Pharmaceutical Holdings Ltd

3737:HKG.HS

Zhongzhi Pharmaceutical Holdings Ltd

Actions
  • Price (HKD)0.93
  • Today's Change0.01 / 1.09%
  • Shares traded425.00k
  • 1 Year change-33.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhongzhi Pharmaceutical Holdings Ltd is a China-based investment holding company. The Company is principally engaged in the research and development, manufacturing and sales of Chinese patent medicines and decoction pieces (consisting of traditional decoction pieces and modern decoction pieces). The Company operates through three segments: pharmaceutical manufacturing segment, operation of chain pharmacies in Zhongshan, Guangdong Province and operation of on-line pharmacies. The Company’s brands include Zeus, Liumian and Caojinghua. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)2.22bn
  • Net income in HKD121.13m
  • Incorporated2014
  • Employees2.74k
  • Location
    Zhongzhi Pharmaceutical Holdings LtdNo.3 Kangtai Road SouthTorch Development ZoneZHONGSHAN ChinaCHN
  • Phone+86 76 085331222
  • Fax+86 76 085318764
  • Websitehttp://www.zeus.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.